2026-02-17, 2:08:18 p.m.
SAN FRANCISCO — February 17, 2026 — Leads & Copy — Kyntra Bio (Nasdaq: KYNB) will participate in upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference.
Formerly FibroGen (Nasdaq: FGEN), Kyntra Bio’s management will present at the Oppenheimer conference on February 26, 2026, from 2:40 PM to 3:10 PM ET. The presentation will be virtual and accessible via webcast.
The Leerink Global Healthcare Conference will feature a Kyntra Bio corporate presentation on March 11, 2026, from 2:20 PM to 2:50 PM ET in Miami, FL. A webcast will also be available for this presentation.
Kyntra Bio’s management team will be available for one-on-one meetings during the conferences. Interested investors should contact their representatives to request a meeting.
Replays of the presentations will be available on the Events & Presentations page of the Investors and Media section of the Kyntra Bio website for 90 days.
Kyntra Bio focuses on developing novel therapies in oncology and rare diseases. Roxadustat (爱瑞卓®, EVRENZO™) is approved in Europe, Japan, and other countries for treating anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
The company is evaluating the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S.
FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for metastatic castration-resistant prostate cancer. This program includes developing FG-3180, an associated CD46-targeted PET biomarker.
Source: Kyntra Bio
